Risk of perioperative discontinuation of SGLT2 inhibitors.
Br J Anaesth
; 133(2): 239-240, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-38834489
ABSTRACT
When sodium-glucose cotransporter-2 (SGLT2) inhibitors were primarily prescribed for treatment of diabetes mellitus, guidelines recommended withholding SGLT2 inhibitors before surgery to mitigate the associated risk of ketoacidosis. However, currently, SGLT2 inhibitors are an established therapy for patients with heart failure, and there is evidence that withholding SGLT2 inhibitors can worsen these patients' cardiovascular risk profile. We present an updated risk-benefit analysis of withholding SGLT2 inhibitors before surgery, focusing on patients with heart failure and addressing the risk of ketoacidosis and its treatment in these patients. Clinicians should consider perioperative continuation of SGLT2 inhibitors when prescribed for treatment of heart failure.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Assistência Perioperatória
/
Inibidores do Transportador 2 de Sódio-Glicose
/
Insuficiência Cardíaca
Limite:
Humans
Idioma:
En
Revista:
Br J Anaesth
Ano de publicação:
2024
Tipo de documento:
Article